MediGene wins dispute over cancer-killing viruses patent');">Comments
MARTINSRIED, Germany (AFX) - MediGene AG said it has successfully won a dispute over its patent on herpex simplex viruses, or cancer-killing HSV, at the European Patent Office.
The patent protects a production method for herpes simplex virus-1 vaccines including specific oncolytic herpes simplex viruses (cancer-killing HSV) developed by MediGene.
University College London and the University Court of the University of Glasgow had opposed the patent.
The patent protection will expire in Sept 2011, but in case of marketing
authorization prior to that date, the protection may be extended by up to five years.
MediGene is developing two strains of oncolytic herpes simplex viruses, designed to selectively multiply in tumor cells, thus destroying the tumour.
The NV1020 strain is currently undergoing a clinical phase I/II trial for the treatment of liver metastases from colorectal carcinoma, and the G207 strain is being examined in a clinical phase I trial for the treatment of malignant brain tumour.
ragnhild.kjetland@afxnews.com
rkj/jc1
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by AFX News and its third party content providers for your personal information only, and neither AFX News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.
Herpes Treatment
|
